References
1. Scott AT, Howe JR: Evaluation and Management of Neuroendocrine Tumors
of the Pancreas. Surg Clin North Am. 2019, 99:793-814.
10.1016/j.suc.2019.04.014
2. Ma ZY, Gong YF, Zhuang HK, et al.: Pancreatic neuroendocrine tumors:
A review of serum biomarkers, staging, and management. World J
Gastroenterol. 2020, 26:2305-2322. 10.3748/wjg.v26.i19.2305
3. Konukiewitz B, Jesinghaus M, Kasajima A, Kloppel G: Neuroendocrine
neoplasms of the pancreas: diagnosis and pitfalls. Virchows Arch. 2022,
480:247-257. 10.1007/s00428-021-03211-5
4. de Herder WW, Hofland J: Insulinoma. Endotext. Feingold KR, Anawalt
B, Blackman MR, et al. (eds): MDText.com, Inc. Copyright © 2000-2023,
MDText.com, Inc., South Dartmouth (MA); 2000.
5. Okabayashi T, Shima Y, Sumiyoshi T, et al.: Diagnosis and management
of insulinoma. World J Gastroenterol. 2013, 19:829-837.
10.3748/wjg.v19.i6.829
6. Magi L, Marasco M, Rinzivillo M, Faggiano A, Panzuto F: Management of
Functional Pancreatic Neuroendocrine Neoplasms. Curr Treat Options
Oncol. 2023. 10.1007/s11864-023-01085-0
7. Kulke MH, Anthony LB, Bushnell DL, et al.: NANETS treatment
guidelines: well-differentiated neuroendocrine tumors of the stomach and
pancreas. Pancreas. 2010, 39:735-752. 10.1097/MPA.0b013e3181ebb168
8. Crippa S, Zerbi A, Boninsegna L, et al.: Surgical management of
insulinomas: short- and long-term outcomes after enucleations and
pancreatic resections. Arch Surg. 2012, 147:261-266.
10.1001/archsurg.2011.1843
9. Service FJ, McMahon MM, O’Brien PC, Ballard DJ: Functioning
insulinoma–incidence, recurrence, and long-term survival of patients:
a 60-year study. Mayo Clin Proc. 1991, 66:711-719.
10.1016/s0025-6196(12)62083-7
10. Sada A, Glasgow AE, Vella A, Thompson GB, McKenzie TJ, Habermann EB:
Malignant Insulinoma: A Rare Form of Neuroendocrine Tumor. World Journal
of Surgery. 2020, 44:2288-2294. 10.1007/s00268-020-05445-x
11. Wynick D, Williams SJ, Bloom SR: Symptomatic secondary hormone
syndromes in patients with established malignant pancreatic endocrine
tumors. N Engl J Med. 1988, 319:605-607. 10.1056/NEJM198809083191003
12. de Mestier L, Hentic O, Cros J, et al.: Metachronous hormonal
syndromes in patients with pancreatic neuroendocrine tumors: a
case-series study. Ann Intern Med. 2015, 162:682-689. 10.7326/M14-2132
13. Clover T, Abdelkader A, Guru Murthy GS: Transformation of a
non-secretory neuroendocrine tumor to insulinoma after treatment with
Sunitinib: A case report and review of the literature. J Oncol Pharm
Pract. 2019, 25:1516-1519. 10.1177/1078155218791309
14. Crona J, Norlen O, Antonodimitrakis P, Welin S, Stalberg P, Eriksson
B: Multiple and Secondary Hormone Secretion in Patients With Metastatic
Pancreatic Neuroendocrine Tumours. J Clin Endocrinol Metab. 2016,
101:445-452. 10.1210/jc.2015-2436
15. Baratelli C, Brizzi MP, Tampellini M, et al.: Intermittent
everolimus administration for malignant insulinoma. Endocrinol Diabetes
Metab Case Rep. 2014, 2014:140047. 10.1530/EDM-14-0047
16. Raymond E, Dahan L, Raoul JL, et al.: Sunitinib malate for the
treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011,
364:501-513. 10.1056/NEJMoa1003825